Hana Klamová - Concepedia

Author

Hana Klamová

Institute of Haematology and Blood Transfusion ORCID

Also Known As

Faber, Edgar, H KLAMOVÁ, H Klamova, H Klamová, H Klamová,, H. KLAMOVA, H. Klamova, H. Klamová, Hana Klamova, Hana Klamová

196

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Institute of Haematology and Blood Transfusion Charles University Masaryk University General University Hospital in Prague University of Bologna

About

Hana Klamová is an author at Institute of Haematology and Blood Transfusion specializing in medicine, hematology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	27	1.3K
2	Health Sciences	11	12	824
3	Engineering	4	4	214
4	Natural Sciences	2	2	64
5	Biochemistry	1	1	52

Hana Klamová

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial Johan Richter, Joëlle Guilhot, Franz Gruber, The Lancet Oncology Hematological MalignancyMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematology	2018	587
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia Kimmo Porkka, Perttu Koskenvesa, Tuija Lundán, Blood	2008	437
Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain Simona Soverini, Caterina De Benedittis, Kateřina Machová Poláková, Blood	2013	162
Expression patterns of microRNAs associated with CML phases and their disease related targets Kateřina Machová Poláková, Tereza Lopotová, Hana Klamová, Molecular Cancer	2011	141
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase Kateřina Machová Poláková, Vojtěch Kulvait, Adela Benesova, Journal of Cancer Research and Clinical Oncology BioinformaticsChronic PhaseRadiation OncologyHematological MalignancyEngineering	2014	77
MicroRNA-451 in chronic myeloid leukemia: miR-451–BCR-ABL regulatory loop? Tereza Lopotová, Markéta Žáčková, Hana Klamová, Leukemia Research Hematological MalignancyChronic Myeloid LeukemiaMedicineEpigenetic RegulationCell Biology	2011	72
Next-generation sequencing for sensitive detection of <i>BCR-ABL1</i> mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients Simona Soverini, Caterina De Benedittis, Kateřina Machová Poláková, Oncotarget	2016	58
Gene Expression Profiling in Chronic Myeloid Leukemia Patients Treated with Hydroxyurea Hana Bruchova, Tereza Borovanova, Hana Klamová, Leukemia & lymphoma/Leukemia and lymphoma EngineeringMixed-phenotype Acute LeukemiaGeneticsImmunologyGene Expression Profiling	2002	57
Selective destruction of leukaemic cells by photo-activation of 5-aminolaevulinic acid-induced protoporphyrin-IX Dana Grebeňová, H Cajthamlová, Jitka Bartošová, Journal of Photochemistry and Photobiology B Biology Leukaemic CellsPhotochemistryBiochemistryMedicineMechanistic Photochemistry	1998	52
High-resolution melt curve analysis: Initial screening for mutations in BCR-ABL kinase domain Kateřina Machová Poláková, Tereza Lopotová, Hana Klamová, Leukemia Research Curve AnalysisEngineeringMedicineComputational BiologyMolecular Biology	2008	51

Page 1